Clinical Trial

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 21, 2026 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-03; most recent amendment 2026-01-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-25
Trial Details
NCT Number NCT07157007
Lead Sponsor Traws Pharma, Inc.
Conditions COVID - 19
Enrollment 90 participants
Start Date 2025-09-16
Primary Completion 2026-02 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-21